Compare GE Vernova Inc (GEV) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs McKesson Corporation — how do they compare? GE Vernova Inc trades at $1,006.55 (market cap $266.16B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: GE Vernova Inc is far larger — about 2.5× McKesson Corporation's market cap, and McKesson Corporation pays the higher dividend (0.4%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and McKesson Corporation for 74 Days on average.
| GEV | MCK | |
|---|---|---|
Market Cap | $266.16B | $108.46B |
Volume | 2,324,165 | 712,607 |
Sector | Industrials | Health |
52-Week High | $1.17K | $995.69 |
52-Week Low | $547.96 | $725.17 |
Typical Hold Time | 36 Days | 74 Days |
Enterprise Value | $255.83B | $115.00B |
Dividend Yield | 0.2% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $997.09, down 3.12% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical signals with support at $985 and resistance at $1,005. Recent Q1 2026 earnings beat expectations with $17.44 EPS, though Q2 missed. The company secured the first US construction permit for its BWRX-300 SMR, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with 2026 revenue projected at $41.4B and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and execution challenges in the wind segment. The stock offers 27% upside to consensus target, supported by strong institutional sentiment and AI infrastructure tailwinds.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
